Cited by 169Immunotherapy and Immune ResponsesImmune responses and vaccinationsNanoparticle-Based Drug Delivery

Eliciting B cell immunity against infectious diseases using nanovaccines

Open access
Singh, Ankur·2021·Nature Nanotechnology

Abstract

Infectious diseases, including the coronavirus disease 2019 (COVID-19) pandemic that has brought the world to a standstill, are emerging at an unprecedented rate with a substantial impact on public health and global economies. For many life-threatening global infectious diseases, such as human immunodeficiency virus (HIV) infection, malaria and influenza, effective vaccinations are still lacking. There are numerous roadblocks to developing new vaccines, including a limited understanding of immune correlates of protection to these global infections. To induce a reproducible, strong immune response against difficult pathogens, sophisticated nanovaccine technologies are under investigation. In contrast to conventional vaccines, nanovaccines provide improved access to lymph nodes, optimal packing and presentation of antigens, and induction of a persistent immune response. This Review provides a perspective on the global trends in emerging nanoscale vaccines for infectious diseases and describes the biological, experimental and logistical problems associated with their development, and how immunoengineering can be leveraged to overcome these challenges.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41565-020-00790-3

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The broadly neutralizing monoclonal antibodies VRC01 neutralize 98% of HIV strains and prevent transmission of antibody-sensitive strains with 75.4% efficacy.

    “Notably, the broadly neutralizing mAbs, VRC01, have recently gained attention thanks to their ability to neutralize 98% of HIV strains167 and prevent transmission of antibody-sensitive strains with 75.4% efficacy168.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Singh, A.
Affiliations
Georgia Institute of Technology (US)
Corresponding author
Singh, Ankur
Venue
Nature Nanotechnology
Published
2020-11-16
Volume
16
Issue
1
Pages
16-24
ISSN
  • 1748-3387 (ISSN-L)
  • 1748-3395
OpenAlex
W3103525807
Cited by
169
References
70
Citations by year
2026: 18 · 2025: 23 · 2024: 28 · 2023: 40 · 2022: 36 · 2021: 23 · 2020: 1
FWCI
2.44
Type
journal article
Language
en
Open access
Locations
  • Nature Nanotechnology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (5R01AI132738-03)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
nanovaccines, B-cell immunity, infectious disease vaccines, immunoengineering, antigen presentation, correlates of protection, HIV, malaria, influenza, COVID-19 pandemic
MeSH terms
Animals, B-Lymphocytes, Communicable Diseases, Humans, Lymph Nodes, Mutation, Vaccines, Antigen Presentation, Antibody-Dependent Enhancement, Nanoparticles, Antibodies, Neutralizing, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review